“We are excited to collaborate with Scienture to enhance its commercial effectiveness,” said Paul Mignon, President, Deployment Solutions, Syneos Health. “Our team is committed to delivering tailored ...

Pointing out that the deal was terminated on March 5, 2025, Aurobindo Pharma said that as Auro Vaccines is not a material subsidiary to the company, the termination was not expected to have any ...

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on aTyr Pharma (ATYR – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $3.99.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Aurobindo Pharma on Wednesday said its subsidiary has terminated a license agreement with Singapore-based Hilleman Laboratories to develop and commercialise a pentavalent vaccine candidate used in ...

It spans pharmaceuticals, hospital systems ... red-carpet photos in front of a step-and-repeat banner emblazoned with logos of corporate sponsors. Guests snacked on canapés and hors d’oeuvres ...

Opinions expressed are those of the author. 2025 is going to be a big year for AI adoption in pharma. By now, most life science companies have at least experimented with one generative AI (GenAI ...

HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased ...

TEL AVIV, Israel, Feb. 27, 2025 /PRNewswire/ -- Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing needle-free, powder-based ...

There is currently no treatment for CLN1. Collaborations Pharmaceuticals, Inc (CPI) is developing an enzyme replacement therapy (ERT) for this disease and has produced a registry for finding ...